Bayer faces potential fine over cholesterol lowering drugBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7310.415a (Published 25 August 2001) Cite this as: BMJ 2001;323:415
- Annette Tuffs, Heidelberg
Bayer, the German company that was forced earlier this month to withdraw a cholesterol lowering drug from the market, might have to pay a fine of DM50000 (£16200; $23400) for withholding from the German authorities information on the drug's potentially fatal interaction with another drug.
Bayer's drug, cerivastatin (Baycol in the United States, Lipobay in the United Kingdom), was withdrawn after 52 deaths occurred in patients taking the drug; 31 of the deaths were in the United States (18 August, p …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial